{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T23:59:19Z","timestamp":1794959959514,"version":"4.9.1"},"reference-count":42,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2024,12,31]]},"DOI":"10.1080\/13696998.2024.2351762","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T06:05:59Z","timestamp":1714975559000},"page":"758-765","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Analysis of long-term clinical and cost impact of etranacogene dezaparvovec for the treatment of hemophilia B population in the United States"],"prefix":"10.1080","volume":"27","author":[{"given":"Songkai","family":"Yan","sequence":"first","affiliation":[{"name":"CSL Behring","place":["King of Prussia, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"McDade","sequence":"additional","affiliation":[{"name":"RTI Health Solutions","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris","family":"Thiruvillakkat","sequence":"additional","affiliation":[{"name":"CSL Behring","place":["King of Prussia, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Rouse","sequence":"additional","affiliation":[{"name":"CSL Behring","place":["King of Prussia, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krupa","family":"Sivamurthy","sequence":"additional","affiliation":[{"name":"CSL Behring","place":["King of Prussia, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Wilson","sequence":"additional","affiliation":[{"name":"RTI Health Solutions","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13998"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.15256\/joc.2011.1.2"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2021.1891088"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-019-02786-9"},{"key":"e_1_3_4_6_1","volume-title":"HEMGENIX\u00ae (etranacogene dezaparvovec-drlb) suspension for intravenous infusion prescribing information","author":"Hemgenix PI","year":"2022","unstructured":"Hemgenix PI. HEMGENIX\u00ae (etranacogene dezaparvovec-drlb) suspension for intravenous infusion prescribing information. King of Prussia, PA: CSL Behring LLC; 2022."},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211644"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2022.2133492"},{"key":"e_1_3_4_9_1","unstructured":"US Census Bureau. Fast facts. US population. 2022."},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166135"},{"key":"e_1_3_4_11_1","unstructured":"CSL Behring. Data on file. Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B: updated analysis based on 36-month data; 2024."},{"key":"e_1_3_4_12_1","unstructured":"US BEA. Price indexes for personal consumption expenditures by type of product. Table 2.4.4U; 2022."},{"key":"e_1_3_4_13_1","unstructured":"CSL Behring. Data on file. Adivo market share data and dosing distribution; 2022."},{"key":"e_1_3_4_14_1","unstructured":"Micromedex. Red book online accessed through micromedex 2.0. Thomson Reuters; 2022."},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-023-01335-x"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S363028"},{"key":"e_1_3_4_17_1","unstructured":"ICER. Institute for Clinical and Economic Review (ICER). Gene therapy for hemophilia B and an update on gene therapy for hemophilia A: effectiveness and value. Draft evidence report. 2022."},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.21311"},{"key":"e_1_3_4_19_1","unstructured":"WFH. World Federation of Hemophilia (WFH). Report on the Annual Global Survey 2020; 2022."},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2009.182"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.05107-11"},{"key":"e_1_3_4_22_1","unstructured":"ECDC. European Centre for Disease Prevention and Control (ECDC). Hepatitis B. In: ECDC. Annual epidemiological report for 2019; 2021."},{"key":"e_1_3_4_23_1","unstructured":"EMA. European Medicines Agency (EMA). Refexia assessment report; 2016."},{"key":"e_1_3_4_24_1","unstructured":"Haemophilia Society. Inhibitors; 2022."},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2019.05.014"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2011.90"},{"key":"e_1_3_4_27_1","unstructured":"Majowicz A van Waes F Timmer N et\u00a0al. Prevalence and affinity\/avidity assessment of pre-existing NABs against AAV2 5 and 8 analyzed in the serum of 300 healthy donors. Human Gene Therapy; 2019. p. A116."},{"key":"e_1_3_4_28_1","unstructured":"NHS. National Health Service (NHS). Von Willebrand Disease; 2020."},{"key":"e_1_3_4_29_1","unstructured":"CMS. Centers for Medicare & Medicaid Services (CMS). 2022 National physician fee schedule relative value file April release; 2022."},{"key":"e_1_3_4_30_1","unstructured":"CMS. Centers for Medicare & Medicaid Services (CMS). 2022 Clinical diagnostic laboratory fee schedule; 2022."},{"key":"e_1_3_4_31_1","volume-title":"ALPROLIX [coagulation factor IX (recombinant), Fc fusion protein], lyophilized powder for solution for intravenous injection prescribing information","author":"Alprolix PI","year":"2020","unstructured":"Alprolix PI. ALPROLIX [coagulation factor IX (recombinant), Fc fusion protein], lyophilized powder for solution for intravenous injection prescribing information. Bioverativ Therapeutics Inc.; 2020."},{"key":"e_1_3_4_32_1","volume-title":"BeneFIX\u00ae [coagulation factor IX (recombinant)] lyophilized powder for solution, for intravenous use prescribing information","author":"BeneFIX PI","year":"2021","unstructured":"BeneFIX PI. BeneFIX\u00ae [coagulation factor IX (recombinant)] lyophilized powder for solution, for intravenous use prescribing information. Philadelphia, PA: Wyeth Pharmaceuticals LLC; 2021."},{"key":"e_1_3_4_33_1","volume-title":"IDELVION [coagulation factor IX (recombinant), albumin fusion protein] lyophilized powder for solution for intravenous injection prescribing information","author":"Idelvion PI","year":"2021","unstructured":"Idelvion PI. IDELVION [coagulation factor IX (recombinant), albumin fusion protein] lyophilized powder for solution for intravenous injection prescribing information. Kankakee, IL: CSL Behring LLC; 2021."},{"key":"e_1_3_4_34_1","volume-title":"IXINITY (coagulation factor IX (recombinant), lyophilized powder for solution for intravenous injection prescribing information","author":"Ixinity PI","year":"2022","unstructured":"Ixinity PI. IXINITY (coagulation factor IX (recombinant), lyophilized powder for solution for intravenous injection prescribing information. Chicago, IL: medexus Pharma, Inc.; 2022."},{"key":"e_1_3_4_35_1","volume-title":"REBINYN\u00ae (coagulation factor IX (recombinant), GlycoPEGylated) lyophilized powder for solution for intravenous injection prescribing information","author":"Rebinyn PI","year":"2017","unstructured":"Rebinyn PI. REBINYN\u00ae (coagulation factor IX (recombinant), GlycoPEGylated) lyophilized powder for solution for intravenous injection prescribing information. Plainsboro, NJ: novo Nordisk Inc; 2017."},{"key":"e_1_3_4_36_1","volume-title":"RIXUBIS [coagulation factor IX (recombinant)] for intravenous injection, lyophilized powder for solution prescribing information","author":"Rixubis PI","year":"2020","unstructured":"Rixubis PI. RIXUBIS [coagulation factor IX (recombinant)] for intravenous injection, lyophilized powder for solution prescribing information. Lexington, MA: baxalta US Inc; 2020."},{"key":"e_1_3_4_37_1","unstructured":"Pipe SW Leebeek FW Recht M et\u00a0al. editors. 52 Week efficacy and safety of etranacogene dezaparvovec in adults with severe or moderate-severe hemophilia B: data from the phase 3 HOPE-B gene therapy trial. [abstract; PB0653]. Res Pract Thromb Haemost. 2021;5(S2):490. Available from: https:\/\/abstracts.isth.org\/abstract\/52-week-efficacy-and-safety-of-etranacogene-dezaparvovec-in-adults-with-severe-or-moderate-severe-hemophilia-b-data-from-the-phase-3-hope-b-gene-therapy-trial\/. Accessed May 7 2024."},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13561-018-0185-7"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003424"},{"key":"e_1_3_4_40_1","unstructured":"Humana. Cost of common dental procedures. 2022."},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-02152-1"},{"key":"e_1_3_4_42_1","volume-title":"Healthcare cost and utilization project (HCUP)","author":"AHRQ HCUP","year":"2020","unstructured":"AHRQ HCUP. Agency for healthcare research and quality (AHRQ). Healthcare cost and utilization project (HCUP). Costs of Emergency Department Visits in the United States, 2017; 2020."},{"key":"e_1_3_4_43_1","unstructured":"AHRQ HCUP. Agency for healthcare research and quality (AHRQ). Healthcare cost and utilization project (HCUP). National Inpatient Hospital Costs: the Most Expensive Conditions by Payer 2017; 2020."}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2024.2351762","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:47:51Z","timestamp":1772779671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2024.2351762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,6]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,31]]}},"alternative-id":["10.1080\/13696998.2024.2351762"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2024.2351762","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-02-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-26","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}